These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 20438515

  • 1. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T, Lanthanum Carbonate Research Group.
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T, Negi S, COLC Research Group.
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS, Finn WF, LAM-302 Study Group.
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T, Ohya M, Negi S, Masumoto AR, Nakashima YM, Iwatani Y, Moribata MK, Yamanaka S, Tatsuta K, Mima T.
    Contrib Nephrol; 2015 Jul; 185():42-55. PubMed ID: 26023014
    [Abstract] [Full Text] [Related]

  • 7. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK, Choi HY, Shin SK, Lee HY.
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [Abstract] [Full Text] [Related]

  • 8. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G, Londrino F, Corbani V, Falqui V, Ardini M, Zattera T, Liguria and Toscana Lanthanum Experience (LITOLAE) Group.
    J Nephrol; 2012 Feb; 25(4):490-6. PubMed ID: 22476966
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T, Hong Z, Matsunaga T, Kaneko Y, Taru Y.
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF, Joy MS, LAM-308 Study Group.
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [Abstract] [Full Text] [Related]

  • 18. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T, LANDMARK Investigators and Committees.
    JAMA; 2021 May 18; 325(19):1946-1954. PubMed ID: 34003226
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskühler A.
    Nephron Clin Pract; 2006 May 18; 102(2):c61-71. PubMed ID: 16224198
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF, Joy MS, Hladik G, Lanthanum Study Group.
    Clin Nephrol; 2004 Sep 18; 62(3):193-201. PubMed ID: 15481851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.